Retatrutide dose escalation in the published trials posts 121–150
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Post #119 answers the question as asked. The question underneath it is different.
Agreed on retatrutide dose escalation, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.
Post #119 and I disagree about the size of the effect, not about the direction.
The hepatic-steatosis rationale follows directly from glucagon receptor agonism promoting fat oxidation in the liver. Mechanistic plausibility in this field has a poor record of predicting clinical outcomes, which is why the trials matter more than the mechanism.
If this contradicts something upthread, the upthread version may well be the better one.
Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.
The part I am sure of is shorter than the part I have written.
Coming back to post #123, because the follow-up matters more than the original answer.
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
Reading rather than answering, but this is the post I would point somebody at.
Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.
The number is defensible. The precision I gave it is not.
A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.
The strength of my opinion here exceeds the strength of my evidence.
I had written a reply contradicting post #127 and deleted it. Here is what survived.
On analysis: a chromatographic purity figure for an investigational compound is harder to interpret than for a well-characterised one, because there is no reference standard in wide circulation and no published impurity profile to compare against.
The disagreement above is smaller than it looks once the terms are fixed.
Dose-response in the phase 2 obesity work was clear across the studied range, with no obvious plateau within it. Extrapolating beyond the highest studied dose from that is exactly the reasoning trials are designed to prevent.
Nothing above should be read as advice about what anyone else should do.
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
Helpful, and easy to find again, which is half of what a good reply is.
Worth separating two things that post #132 runs together.
Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.
It reads as pedantry until the day it does not.
Collapsed as off-topic by two members at trust level 3 or above
Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.
It is a small point and it changes the answer, which is an awkward combination.
The reason retatrutide dose escalation is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.
Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.
Post #136 and I disagree about the size of the effect, not about the direction.
On analysis: a chromatographic purity figure for an investigational compound is harder to interpret than for a well-characterised one, because there is no reference standard in wide circulation and no published impurity profile to compare against.
Confirming post #138 from a second method, which matters more than confirming it from a second person.
Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase 2 trial without a dual-agonist comparator arm cannot distinguish the two.
How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does not establish safety, durability, or whether real humans differ from the selected population.
That is my reading. Someone else read the same page differently and was reasonable.
Whatever the answer on retatrutide dose escalation turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
Post #141 is the version of this I will quote in future. One addition.
Dose-response in the phase 2 obesity work was clear across the studied range, with no obvious plateau within it. Extrapolating beyond the highest studied dose from that is exactly the reasoning trials are designed to prevent.
A guess, clearly labelled as one.
I came in to disagree and I am leaving without a disagreement.
I had written a reply contradicting post #145 and deleted it. Here is what survived.
One caution on retatrutide dose escalation: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
The version of retatrutide dose escalation that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Everything in post #145 holds. The case it does not cover is the one I have.
A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.
The claim is narrower than it sounds, and deliberately so.
Narrowing post #149, because the general version has more than one answer.
Dose escalation in the published trials: the protocols started at lower doses and escalated by defined steps. The step sizes are documented and they may or may not match what someone self-prescribing would choose.
If the premise is wrong, everything after it is decoration.